真实世界临床实践中接受阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者中符合与不符合IMbrave150三期试验入组标准者的结局
研究纳入936例接受阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者,其中404例符合IMbrave150试验入组标准,532例不符合。符合组中位无进展生存期7.4个月 vs 不符合组5.6个月(p=0.002),中位总生存期26.5个月 vs 18.8个月(p<0.001)。在改良白蛋白-胆红素分级1或2a的患者中,两组无进展生存期或总生存期无显著差异。
要点
- 符合IMbrave150入组标准者中位PFS 7.4个月,不符合者5.6个月(p=0.002)。
- 符合组中位OS 26.5个月,不符合组18.8个月(p<0.001)。
- mALBI分级1或2a患者中,符合与不符合组PFS和OS无显著差异。
核心结论
- 接受阿替利珠单抗联合贝伐珠单抗治疗且符合IMbrave150三期试验入组标准的患者,以及不符合入组标准但肝功能良好的患者,生存预后良好。
研究设计与样本
- 真实世界 setting 下纳入936例接受阿替利珠单抗联合贝伐珠单抗治疗的肝细胞癌患者,其中404例符合IMbrave150试验入组标准(IMbrave150组),532例不符合(非IMbrave150组)。
主要发现
- IMbrave150组与非IMbrave150组中位无进展生存期分别为7.4个月和5.6个月(p=0.002)。
- 多变量分析显示,非B非C肝细胞癌病因(HR 1.173)、甲胎蛋白≥100 ng/mL(HR 1.472)、巴塞罗那临床肝癌分期≥C(HR 1.318)、改良白蛋白-胆红素分级2b或3(HR 1.476)与无进展生存期独立相关。
- IMbrave150组与非IMbrave150组中位总生存期分别为26.5个月和18.8个月(p<0.001)。
- 多变量分析显示,东部肿瘤协作组体能状态≥2(HR 1.986)、甲胎蛋白≥100 ng/mL(HR 1.481)、改良白蛋白-胆红素分级2b或3(HR 2.037)与总生存期独立相关。
- 亚组分析中,改良白蛋白-胆红素分级1或2a的患者中,两组无进展生存期或总生存期无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atezolizumab plus bevacizumab (Atezo/Bev) is frequently selected as the primary systemic therapy for hepatocellular carcinoma (HCC). AIMS: To investigate the outcomes of patients with HCC treated with Atezo/Bev in a real-world setting based on whether they met the inclusion criteria for the phase 3 IMbrave150 trial. METHODS: A total of 936 patients were enrolled. There were 404 patients who met the inclusion criteria of the phase 3 IMbrave150 trial (IMbrave150 group) and 532 who did not (non-IMbrave150 group). RESULTS: Median progression-free survival (PFS) in the IMbrave150 and non-IMbrave150 groups was 7.4 months and 5.6 months (p = 0.002). Multivariable analysis revealed that non-B, non-C HCC aetiology (hazard ratio [HR], 1.173), α-fetoprotein ≥100 ng/mL (HR, 1.472), Barcelona Clinic Liver Cancer stage ≥ C (HR, 1.318), and modified albumin-bilirubin (mALBI) grade 2b or 3 (HR, 1.476) are independently associated with PFS. Median overall survival (OS) in the IMbrave150 and non-Imbrave150 groups was 26.5 and 18.8 months (p < 0.001). Multivariable analysis revealed that Eastern Cooperative Oncology Group performance status ≥2 (HR, 1.986), α-fetoprotein ≥100 ng/mL (HR, 1.481), and mALBI grade 2b or 3 (HR, 2.037) are independently associated with OS. In subgroup analysis, there were no significant differences in PFS or OS between these groups among patients with mALBI grade 1 or 2a. CONCLUSIONS: Patients who are treated with Atezo/Bev and meet the inclusion criteria for the phase 3 IMbrave150 trial, as well as those who do not meet the inclusion criteria but have good liver function, have a good prognosis for survival.
引用
- Tada T, Kumada T, Hiraoka A, et al. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial. Aliment Pharmacol Ther. 2024. PMID: 38716823. doi:10.1111/apt.18037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。